Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Porter

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|April 27, 2010
Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overloadJohn-Paul Carpenter, Francisco Alpendurada, Monica Deac, et al.
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.
Blood Cells, Molecules & Diseases|February 9, 2016
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS studyAli T Taher, M Domenica Cappellini, Yesim Aydinok, et al.
Blood|January 4, 2014
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)Dudley J Pennell, John B Porter, Antonio Piga, et al.
Blood Advances|February 8, 2024
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiencyEduard J van Beers, Hanny Al-Samkari, Rachael F Grace, et al.
Transfusion|June 3, 2008
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusionsEllen B Fung, Paul R Harmatz, Meredith Milet, et al.
British Journal of Haematology|October 27, 2025
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trialKhaled M Musallam, Ali T Taher, John B Porter, et al.
Pediatric Hematology and Oncology|August 3, 2010
Transfusion and chelation practices in sickle cell disease: a regional perspectiveElliott P Vichinsky, Kwaku Ohene-Frempong, Swee Lay Thein, et al.
Circulation|June 19, 2013
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart AssociationDudley J Pennell, James E Udelson, Andrew E Arai, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|March 28, 2017
Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemiaPaul Kirk, Mary Sheppard, John-Paul Carpenter, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|April 27, 2010
Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overloadJohn-Paul Carpenter, Francisco Alpendurada, Monica Deac, et al.
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.
Blood Cells, Molecules & Diseases|February 9, 2016
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS studyAli T Taher, M Domenica Cappellini, Yesim Aydinok, et al.
Blood|January 4, 2014
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)Dudley J Pennell, John B Porter, Antonio Piga, et al.
Blood Advances|February 8, 2024
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiencyEduard J van Beers, Hanny Al-Samkari, Rachael F Grace, et al.
Transfusion|June 3, 2008
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusionsEllen B Fung, Paul R Harmatz, Meredith Milet, et al.
British Journal of Haematology|October 27, 2025
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trialKhaled M Musallam, Ali T Taher, John B Porter, et al.
Pediatric Hematology and Oncology|August 3, 2010
Transfusion and chelation practices in sickle cell disease: a regional perspectiveElliott P Vichinsky, Kwaku Ohene-Frempong, Swee Lay Thein, et al.
Circulation|June 19, 2013
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart AssociationDudley J Pennell, James E Udelson, Andrew E Arai, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|March 28, 2017
Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemiaPaul Kirk, Mary Sheppard, John-Paul Carpenter, et al.
Pageof 13